cabergoline has been researched along with tipranavir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, KS; Cabeza de Vaca, I; Deshmukh, M; Ghahremanpour, MM; Ippolito, JA; Jorgensen, WL; Liosi, ME; Tirado-Rives, J; Zhang, CH | 1 |
1 review(s) available for cabergoline and tipranavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for cabergoline and tipranavir
| Article | Year |
|---|---|
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
Topics: | 2020 |